insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

VIRI · Virios Therapeutics, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D$2.67M-$14.52M$2.57M$2.44M-$535.2K$336.1K$343.7K-
SG&A$2.41M-$1.29M$1.35M$1.99M-$1.77M$733.7K$970.4K-
Total Operating Expenses$5.08M-$15.81M$3.92M$4.43M-$2.30M$1.07M$1.31M-
D&A----$17.0K-----
Operating Income($5.08M)-($15.81M)($3.92M)($4.43M)-($2.30M)($1.07M)($1.31M)-
Interest Expense----------
Income Tax----------
Net Income($4.99M)-($15.74M)($3.81M)($10.92M)-($2.28M)($1.05M)($1.29M)-
EPS - Basic($0.15)-($8.20)($1.99)($8.45)-($2.05)($0.05)($0.07)-
EPS - Diluted($0.15)-($8.20)($1.99)($8.45)-($2.05)($0.05)($0.07)-

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$13.23M$6.52M$10.13M$13.40M$17.54M$14.85M$2.04M$3.02M$2.38M$3.32M
Accounts Receivable----------
Inventory----------
Accounts Payable$144.4K$760.9K$584.6K$498.1K$1.15M$1.23M$455.0K$217.8K$196.8K$111.9K
Current Assets$15.00M$8.43M$11.66M$14.70M$19.16M$16.54M$2.28M$3.64M$3.22M$4.17M
Total Assets$95.21M$90.17M$91.99M$96.69M$96.98M$94.31M$2.28M$3.64M$3.22M$4.17M
Current Liabilities$2.56M$3.06M$2.60M$1.89M$2.58M$3.18M$1.33M$500.1K$570.1K$358.5K
Long-term Debt----------
Total Liabilities$14.58M$15.27M$14.61M$14.15M$14.24M$30.03M$1.33M$500.1K$570.1K$358.5K
Stockholders' Equity$80.62M$74.90M$7.26M$6.88M$7.09M($10.12M)$949.4K$3.14M$2.65M$3.81M
Retained Earnings($113.06M)($108.08M)($104.30M)($88.55M)($84.74M)($73.82M)($66.09M)($63.81M)($62.76M)($61.47M)

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow($4.59M)---($4.68M)---($937.4K)-
Investing Cash Flow----------
Financing Cash Flow$11.29M---$7.37M-----
CapEx----------
Free Cash Flow----------

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income----------
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets-5.2%--17.1%-3.9%-11.3%--99.9%-28.9%-40.0%-
Return on equity-6.2%--216.9%-55.4%-154.2%--240.2%-33.5%-48.6%-
Return on invested capital----------
Liquidity
Current ratio5.862.764.497.807.435.211.717.275.6611.62
Quick ratio5.862.764.497.807.435.211.717.275.6611.62
Cash ratio5.172.133.907.116.804.671.536.044.179.25
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage----------
Equity multiplier1.181.2012.6714.0613.69-9.322.401.161.211.09
Liabilities / Assets0.150.170.160.150.150.320.580.140.180.09
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B----------
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)-14.6%--587.0%-266.7%-237.1%--80.6%-11.0%-
Net income growth (YoY)54.4%--590.3%-262.7%-746.0%--84.7%-10.4%-
EPS growth (YoY)98.2%--300.0%-3880.0%-11971.4%--3316.7%-12.5%-
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)1037.6%-664.5%119.4%167.0%--80.1%--43.4%-48.0%

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing Virios Therapeutics against the 5 most active filers in the same SIC group.